Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia

Trial Profile

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2018

At a glance

  • Drugs Vixotrigine (Primary)
  • Indications Trigeminal neuralgia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SURGE
  • Sponsors Biogen
  • Most Recent Events

    • 21 Dec 2018 This trial was suspended in Austria, according to European Clinical Trials Database.
    • 19 Dec 2018 Planned End Date changed from 26 Nov 2022 to 7 Aug 2023.
    • 19 Dec 2018 Planned primary completion date changed from 26 Nov 2020 to 9 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top